Third Harmonic Bio, Inc. (THRD)
NASDAQ: THRD · IEX Real-Time Price · USD
10.46
-0.87 (-7.68%)
Apr 25, 2024, 4:30 PM EDT - Market closed
Company Description
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases.
The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions.
The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019.
Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
Third Harmonic Bio, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 15, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Ms. Natalie C. Holles |
Contact Details
Address: 1700 Montgomery Street, Suite 210 San Francisco, California 94111 United States | |
| Phone | (209) 727-2457 |
| Website | thirdharmonicbio.com |
Stock Details
| Ticker Symbol | THRD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001923840 |
| CUSIP Number | 88427A107 |
| ISIN Number | US88427A1079 |
| Employer ID | 83-4553503 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Natalie C. Holles | Chief Executive Officer and Director |
| Dr. Edward R. Conner M.D. | Chief Medical Officer |
| Christopher Murphy | Chief Financial and Business Officer |
| Julie Person | Chief Administrative Officer |
| Steven P. Sweeney | Senior Vice President of Development Operations |
| Ommer Chohan | Treasurer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | ARS | Filing |
| Apr 18, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | 144 | Filing |
| Apr 10, 2024 | 144 | Filing |
| Apr 4, 2024 | 144 | Filing |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 10-K | Annual Report |